A comprehensive overview of post-stroke depression treatment options.
Journal
International clinical psychopharmacology
ISSN: 1473-5857
Titre abrégé: Int Clin Psychopharmacol
Pays: England
ID NLM: 8609061
Informations de publication
Date de publication:
27 Dec 2023
27 Dec 2023
Historique:
medline:
4
1
2024
pubmed:
4
1
2024
entrez:
3
1
2024
Statut:
aheadofprint
Résumé
Nearly one-third of all stroke patients develop depression at any time after a stroke, and its presence is associated with unfavorable outcomes. This narrative review aims to provide a synopsis of possible pharmacological and non-pharmacological treatment modalities for post-stroke depression (PSD). Several studies have demonstrated the efficacy and safety of selective serotonin reuptake inhibitors in treating the symptoms of this clinical condition. The treatment of PSD has been recently enhanced by innovative approaches, such as cognitive-behavioral therapy, virtual reality, telehealth, repetitive transcranial magnetic stimulation, and non-conventional therapies, which might improve depression treatment in stroke survivors. Future high-quality randomized controlled trials are necessary to confirm this hypothesis.
Identifiants
pubmed: 38170802
doi: 10.1097/YIC.0000000000000532
pii: 00004850-990000000-00115
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Abd TT, Jacobson TA (2011). Statin-induced myopathy: a review and update. Expert Opin Drug Saf 10:373–387.
Agius M, Bonnici H (2017). Antidepressants in use in clinical practice. Psychiatr Danub 29:667–671.
Alajbegovic A, Djelilovic-Vranic J, Nakicevic A, Todorovic L, Tiric-Campara M (2014). Post stroke depression. Med Arch 68:47–50.
Alemanno F, Houdayer E, Emedoli D, Locatelli M, Mortini P, Mandelli C, et al. (2019). Efficacy of virtual reality to reduce chronic low back pain: proof-of-concept of a non-pharmacological approach on pain, quality of life, neuropsychological and functional outcome. PLoS One 14:e0216858.
Alexopoulos GS, Meyers BS, Young RC, Campbell S, Silbersweig D, Charlson M (1997). ‘Vascular depression’ hypothesis. Arch Gen Psychiatry 54:915–922.
Alexopoulos GS, Wilkins VM, Marino P, Kanellopoulos D, Reding M, Sirey JA, et al. (2012). Ecosystem focused therapy in poststroke depression: a preliminary study. Int J Geriatr Psychiatry 27:1053–1060.
Almeida OP, Xiao J (2007). Mortality associated with incident mental health disorders after stroke. Aust N Z J Psychiatry 41:274–281.
American Psychiatric Association (2022). Diagnostic and Statistical Manual of Mental Disorders (DSM-V-TR). American Psychiatric Association.
Andrews JM, Ninan PT, Nemeroff CB (1996). Venlafaxine: a novel antidepressant that has a dual mechanism of action. Depression 4:48–56.
Angell M, Kassirer JP (1998). Alternative medicine--the risks of untested and unregulated remedies. N Engl J Med 339:839–841.
Aragona B, De Luca R, Piccolo A, Le Cause M, Destro M, Casella C, et al. (2018). Is bupropion useful in the treatment of post-stroke thalamic apathy? A case report and considerations. Funct Neurol 33:213–216.
Avery D, Winokur G (1976). Mortality in depressed patients treated with electroconvulsive therapy and antidepressants. Arch Gen Psychiatry 33:1029–1037.
Baker GB, Coutts RT, Mckenna KF, Sherry-Mckenna RL (1992). Insights into the mechanisms of action of the MAO inhibitors phenelzine and tranylcypromine: a review. J Psychiatry Neurosci 17:206–214.
Balunov OA, Sadov OG, Alemasova A (1990). Therapy of depressions in post-stroke patients. Alaska Med 32:20–29.
Beck AT (2019). A 60-year evolution of cognitive theory and therapy. Perspect Psychol Sci 14:16–20.
Bella R, Ferri R, Cantone M, Pennisi M, Lanza G, Malaguarnera G, et al. (2011). Motor cortex excitability in vascular depression. Int J Psychophysiol 82:248–253.
Beutel ME, Klein EM, Brahler E, Reiner I, Junger C, Michal M, et al. (2017). Loneliness in the general population: prevalence, determinants and relations to mental health. BMC Psychiatry 17:97.
Blumberg MJ, Vaccarino SR, Mcinerney SJ (2020). Procognitive effects of antidepressants and other therapeutic agents in major depressive disorder: a systematic review. J Clin Psychiatry 81:19r13200.
Busse E, Simpson D (1983). Depression and antidepressants and the elderly. J Clin Psychiatry 44:35–39.
Carson AJ, Mcwhirter L (2022). Cognitive behavioral therapy: principles, science, and patient selection in neurology. Semin Neurol 42:114–122.
Chen Y, Li J, Liao M, He Y, Dang C, Yu J, et al. (2023). Efficacy and safety of agomelatine versus SSRIs/SNRIs for post-stroke depression: a systematic review and meta-analysis of randomized controlled trials. Int Clin Psychopharmacol. doi: 10.1097/YIC.0000000000000509.
doi: 10.1097/YIC.0000000000000509
Chollet F, Tardy J, Albucher JF, Thalamas C, Berard E, Lamy C, et al. (2011). Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol 10:123–130.
Cipresso P, Giglioli IAC, Raya MA, Riva G (2018). The past, present, and future of virtual and augmented reality research: a network and cluster analysis of the literature. Front Psychol 9:2086.
Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 391:1357–1366.
Congiu P, Puligheddu M, Figorilli M, Ferri R (2018). Periodic leg movements during sleep and cardiovascular and/or cerebrovascular morbidity. Curr Sleep Med Rep 4:58–64.
Cravello L, Caltagirone C, Spalletta G (2009). The SNRI venlafaxine improves emotional unawareness in patients with post-stroke depression. Hum Psychopharmacol 24:331–336.
Cross JG, May BR, Mai PQM, Anderson E, Welsh C, Chandran S, et al. (2023). A systematic review and evaluation of post-stroke depression clinical practice guidelines. J Stroke Cerebrovasc Dis 32:107292.
Currier MB, Murray GB, Welch CC (1992). Electroconvulsive therapy for post-stroke depressed geriatric patients. J Neuropsychiatry Clin Neurosci 4:140–144.
Das J, G KR (2018). Post stroke depression: the sequelae of cerebral stroke. Neurosci Biobehav Rev 90:104–114.
Dela Pena I, Gevorkiana R, Shi WX (2015). Psychostimulants affect dopamine transmission through both dopamine transporter-dependent and independent mechanisms. Eur J Pharmacol 764:562–570.
Deng L, Qiu S, Yang Y, Wang L, Li Y, Lin J, et al. (2018). Efficacy and tolerability of pharmacotherapy for post-stroke depression: a network meta-analysis. Oncotarget 9:23718–23728.
Dennis M, Forbes J, Graham C, Hackett M, Hankey GJ, House A, et al. (2020). Fluoxetine to improve functional outcomes in patients after acute stroke: the FOCUS RCT. Health Technol Assess 24:1–94.
Dobkin RD, Mann SL, Gara MA, Interian A, Rodriguez KM, Menza M (2020). Telephone-based cognitive behavioral therapy for depression in Parkinson disease: a randomized controlled trial. Neurology 94:e1764–e1773.
Drouin A, Thorin-Trescases N, Hamel E, Falck JR, Thorin E (2007). Endothelial nitric oxide synthase activation leads to dilatory H2O2 production in mouse cerebral arteries. Cardiovasc Res 73:73–81.
Drouot X, Moutereau S, Nguyen JP, Lefaucheur JP, Creange A, Remy P, et al. (2003). Low levels of ventricular CSF orexin/hypocretin in advanced PD. Neurology 61:540–543.
Feighner JP (1999). Mechanism of action of antidepressant medications. J Clin Psychiatry 60(Suppl 4):4–11; discussion 12.
Feng C, Fang M, Liu XY (2014). The neurobiological pathogenesis of poststroke depression. ScientificWorldJournal 2014:521349.
Ferri R, Koo BB, Picchietti DL, Fulda S (2017). Periodic leg movements during sleep: phenotype, neurophysiology, and clinical significance. Sleep Med 31:29–38.
Ferri R, Mogavero MP, Bruni O, Picchietti DL, Delrosso LM (2023). Periodic leg movements during sleep associated with antidepressants: a meta-analysis. Neurosci Biobehav Rev 148:105126.
Figorilli M, Puligheddu M, Congiu P, Ferri R (2017). The clinical importance of periodic leg movements in sleep. Curr Treat Options Neurol 19:10.
Fink M (2001). Convulsive therapy: a review of the first 55 years. J Affect Disord 63:1–15.
Focus Trial Collaboration (2019). Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. Lancet 393:265–274.
Frank D, Gruenbaum BF, Zlotnik A, Semyonov M, Frenkel A, Boyko M (2022). Pathophysiology and current drug treatments for post-stroke depression: a review. Int J Mol Sci 23:15114.
Gainotti G, Marra C (2002). Determinants and consequences of post-stroke depression. Curr Opin Neurol 15:85–89.
Gainotti G, Azzoni A, Razzano C, Lanzillotta M, Marra C, Gasparini F (1997). The Post-Stroke Depression Rating Scale: a test specifically devised to investigate affective disorders of stroke patients. J Clin Exp Neuropsychol 19:340–356.
Gao J, Lin M, Zhao J, Bi S, Ni Z, Shang X (2017). Different interventions for post-ischaemic stroke depression in different time periods: a single-blind randomized controlled trial with stratification by time after stroke. Clin Rehabil 31:71–81.
Gao W, Xue F, Yu B, Yu S, Zhang W, Huang H (2023). Repetitive transcranial magnetic stimulation for post-stroke depression: an overview of systematic reviews. Front Neurol 14:930558.
Gill D, Hatcher S (2000). Antidepressants for depression in people with physical illness. Cochrane Database Syst Rev 4:CD001312.
Green B (2011). Focus on agomelatine. Curr Med Res Opin 27:745–749.
Gu J, Huang H, Chen K, Huang G, Huang Y, Xu H (2020). Are they necessary? Preventive therapies for post-stroke depression: a meta-analysis of RCTs. Psychiatry Res 284:112670.
Guaiana G, Gupta S, Chiodo D, Davies SJ, Haederle K, Koesters M (2013). Agomelatine versus other antidepressive agents for major depression. Cochrane Database Syst Rev 12:CD008851.
Hackam DG, Mrkobrada M (2012). Selective serotonin reuptake inhibitors and brain hemorrhage: a meta-analysis. Neurology 79:1862–1865.
Hamilton M (1980). Rating depressive patients. J Clin Psychiatry 41:21–24.
Hansen RA, Khodneva Y, Glasser SP, Qian J, Redmond N, Safford MM (2016). Antidepressant medication use and its association with cardiovascular disease and all-cause mortality in the reasons for geographic and racial differences in stroke (REGARDS) study. Ann Pharmacother 50:253–261.
Hibbard MR, Stein PS, Gordon WA, Sliwinski M (1992). Structured assessment of depression in brain damaged individuals (SADBD): administration and scoring manual. Mt Sinai Center, New York.
Hilari K, Owen S, Farrelly SJ (2007). Proxy and self-report agreement on the Stroke and Aphasia Quality of Life Scale-39. J Neurol Neurosurg Psychiatry 78:1072–1075.
House A, Dennis M, Mogridge L, Warlow C, Hawton K, Jones L (1991). Mood disorders in the year after first stroke. Br J Psychiatry 158:83–92.
House A, Knapp P, Bamford J, Vail A (2001). Mortality at 12 and 24 months after stroke may be associated with depressive symptoms at 1 month. Stroke 32:696–701.
Jackson WK, Roose SP, Glassman AH (1987). Cardiovascular toxicity and tricyclic antidepressants. Biomed Pharmacother 41:377–382.
Jorge RE, Robinson RG, Tateno A, Narushima K, Acion L, Moser D, et al. (2004). Repetitive transcranial magnetic stimulation as treatment of poststroke depression: a preliminary study. Biol Psychiatry 55:398–405.
Kotan D, Deniz O, Aygul R, Yildirim A (2013). Acute cerebral ischaemia: relationship between serum and cerebrospinal fluid orexin-a concentration and infarct volume. J Int Med Res 41:404–409.
Krishnan KR (2000). Depression as a contributing factor in cerebrovascular disease. Am Heart J 140:70–76.
Kucukalic A, Bravo-Mehmedbasic A, Kulenovic AD, Suljic-Mehmedika E (2007). Venlafaxine efficacy and tolerability in the treatment of post-stroke depression. Psychiatr Danub 19:56–60.
Kvedar J, Coye MJ, Everett W (2014). Connected health: a review of technologies and strategies to improve patient care with telemedicine and telehealth. Health Aff (Millwood) 33:194–199.
Kwakkel G, Wagenaar RC, Kollen BJ, Lankhorst GJ (1996). Predicting disability in stroke--a critical review of the literature. Age Ageing 25:479–489.
Ladwig S, Werheid K, Sudmeyer M, Volz M (2023). Predictors of post-stroke depression: Validation of established risk factors and introduction of a dynamic perspective in two longitudinal studies. Front Psychiatry 14:1093918.
Lanctot KL, Lindsay MP, Smith EE, Sahlas DJ, Foley N, Gubitz G, et al.; Management of Mood, Cognition and Fatigue Following Stroke Best Practice Writing Group, the Heart & Stroke Canadian Stroke Best Practices and Quality Advisory Committee; in collaboration with the Canadian Stroke Consortium (2020). Canadian Stroke Best Practice Recommendations: Mood, Cognition and Fatigue following Stroke, 6th edition update 2019. Int J Stroke 15:668–688.
Lauritzen L, Clemmesen L, Klysner R, Loldrup D, Lunde M, Schaumburg E, et al. (1992). Combined treatment with imipramine and mianserin a controlled pilot study. Pharmacopsychiatry 25:182–186.
Laver KE, Adey-Wakeling Z, Crotty M, Lannin NA, George S, Sherrington C (2020). Telerehabilitation services for stroke. Cochrane Database Syst Rev 1:CD010255.
Lavu VK, Mohamed RA, Huang R, Potla S, Bhalla S, Al Qabandi Y, et al. (2022). Evaluation and treatment of depression in stroke patients: a systematic review. Cureus 14:e28137.
Lazarus LW, Moberg PJ, Langsley PR, Lingam VR (1994). Methylphenidate and nortriptyline in the treatment of poststroke depression: a retrospective comparison. Arch Phys Med Rehabil 75:403–406.
Legg LA, Tilney R, Hsieh CF, Wu S, Lundstrom E, Rudberg AS, et al. (2019). (2019) Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst Rev 2019:CD009286.
Lenzi GL, Altieri M, Maestrini I (2008). Post-stroke depression. Rev Neurol (Paris) 164:837–840.
Li F, Gu DX (2006). Treatment for post-stroke depression. Chinese J Clin Rehabilitation 10:129–132.
Li X, Zhang C (2020). Comparative efficacy of nine antidepressants in treating Chinese patients with post-stroke depression: A network meta-analysis. J Affect Disord 266:540–548.
Li GH, Cheung CL, Chung AK, Cheung BM, Wong IC, Fok MLY, et al. (2022). Evaluation of bi-directional causal association between depression and cardiovascular diseases: a Mendelian randomization study. Psychol Med 52:1765–1776.
Li J, Yang L, Lv R, Kuang J, Zhou K, Xu M (2023). Mediating effect of post-stroke depression between activities of daily living and health-related quality of life: meta-analytic structural equation modeling. Qual Life Res 32:331–338.
Liao W, Chen D, Wu J, Liu K, Feng J, Li H, et al. (2023). Risk factors for post-stroke depression in patients with mild and moderate strokes. Medicine (Baltim) 102:e34157.
Lin C, Ren Y, Lu A (2023). The effectiveness of virtual reality games in improving cognition, mobility, and emotion in elderly post-stroke patients: a systematic review and meta-analysis. Neurosurg Rev 46:167.
Lipsey JR, Robinson RG, Pearlson GD, Rao K, Price TR (1984). Nortriptyline treatment of post-stroke depression: a double-blind study. Lancet 1:297–300.
Loubinoux I, Kronenberg G, Endres M, Schumann-Bard P, Freret T, Filipkowski RK, et al. (2012). Post-stroke depression: mechanisms, translation and therapy. J Cell Mol Med 16:1961–1969.
Malzberg B (1937). Mortality among patients with involution melancholia. Am J Psychiatry 93:1231–1238.
Manconi M, Fanfulla F, Ferri R, Miano S, Haba-Rubio J, Heinzer R, et al. (2018). Periodic limb movements during sleep in stroke/TIA: prevalence, course, and cardiovascular burden. Neurology 90:e1663–e1672.
Masand P, Murray GB, Pickett P (1991). Psychostimulants in post-stroke depression. J Neuropsychiatry Clin Neurosci 3:23–27.
Mead G, Dennis M; FOCUS trial Collaboration (2020). Feasibility of reporting results of large randomised controlled trials to participants: experience from the Fluoxetine Or Control Under Supervision (FOCUS) trial. BMJ Open 10:e040492.
Medeiros GC, Roy D, Kontos N, Beach SR (2020). Post-stroke depression: a 2020 updated review. Gen Hosp Psychiatry 66:70–80.
Mendels J, Cochrane C (1968). The nosology of depression: the endogenous-reactive concept. Am J Psychiatry 124(Suppl):1–11.
Mogavero MP, Godos J, Grosso G, Caraci F, Ferri R (2023). Rethinking the role of orexin in the regulation of REM sleep and appetite. Nutrients 15:3679.
Montgomery S (2006). Serotonin noradrenaline reuptake inhibitors: logical evolution of antidepressant development. Int J Psychiatry Clin Pract 10(Suppl 2):5–11.
Mortensen JK, Andersen G (2021). Pharmacological management of post-stroke depression: an update of the evidence and clinical guidance. Expert Opin Pharmacother 22:1157–1166.
Murray GB, Shea V, Conn DK (1986). Electroconvulsive therapy for poststroke depression. J Clin Psychiatry 47:258–260.
Nambiar VK, Parvathy J, Philip TM, Abhijith K, Sreeni S, Panicker NK, et al. (2022). Fluoxetine or venlafaxine for early post stroke depression. Neurol India 70:2407–2410.
Neil HP (2023). Stroke rehabilitation. Crit Care Nurs Clin North Am 35:95–99.
Nelson JC, Charney DS (1980). Primary affective disorder criteria and the endogenous-reactive distinction. Arch Gen Psychiatry 37:787–793.
Nutt DJ, Lingford-Hughes A, Erritzoe D, Stokes PR (2015). The dopamine theory of addiction: 40 years of highs and lows. Nat Rev Neurosci 16:305–312.
O’brien JT, Firbank MJ, Krishnan MS, Van Straaten EC, Van Der Flier WM, Petrovic K, et al.; LADIS Group (2006). White matter hyperintensities rather than lacunar infarcts are associated with depressive symptoms in older people: the LADIS study. Am J Geriatr Psychiatry 14:834–841.
On BI, Vidal X, Berger U, Sabate M, Ballarin E, Maisterra O, et al. (2022). Antidepressant use and stroke or mortality risk in the elderly. Eur J Neurol 29:469–477.
Ousdal OT, Brancati GE, Kessler U, Erchinger V, Dale AM, Abbott C, et al. (2022). The Neurobiological effects of electroconvulsive therapy studied through magnetic resonance: what have we learned, and where do we go? Biol Psychiatry 91:540–549.
Panerai S, Tasca D, Musso S, Catania V, Ruggeri F, Raggi A, et al. (2016). Group intensive cognitive activation in patients with major or mild neurocognitive disorder. Front Behav Neurosci 10:34.
Panerai S, Raggi A, Tasca D, Musso S, Gelardi D, Prestianni G, et al. (2021). Telephone-based reality orientation therapy for patients with dementia: a pilot study during the COVID-19 outbreak. Am J Occup Ther 75:7502205130p1–7502205130p9.
Panerai S, Catania V, Rundo F, Tasca D, Musso S, Babiloni C, et al. (2023). Functional living skills in patients with major neurocognitive disorder due to degenerative or non-degenerative conditions: effectiveness of a non-immersive virtual reality training. Sensors (Basel) 23:1896.
Pop-Jordanova N (2021). Grief: aetiology, symptoms and management. Pril (Makedon Akad Nauk Umet Odd Med Nauki) 42:9–18.
Qin B, Chen H, Gao W, Zhao LB, Zhao MJ, Qin HX, et al. (2018). Efficacy, acceptability, and tolerability of antidepressant treatments for patients with post-stroke depression: a network meta-analysis. Braz J Med Biol Res 51:e7218.
Qiu X, Lan Y, Miao J, Pan C, Sun W, Li G, et al. (2023). Depressive symptom dimensions predict the treatment effect of repetitive transcranial magnetic stimulation for post-stroke depression. J Psychosom Res 171:111382.
Quinn TJ (2019). Fluoxetine in stroke (FOCUS) trial-reasons to be cheerful about antidepressants in stroke? Ann Transl Med 7:S131.
Raggi A, Iannaccone S, Marcone A, Ginex V, Ortelli P, Nonis A, et al. (2007). The effects of a comprehensive rehabilitation program of Alzheimer’s Disease in a hospital setting. Behav Neurol 18:1–6.
Raggi A, Tasca D, Ferri R (2017). A brief essay on non-pharmacological treatment of Alzheimer’s disease. Rev Neurosci 28:587–597.
Rasmussen A, Lunde M, Poulsen DL, Sorensen K, Qvitzau S, Bech P (2003). A double-blind, placebo-controlled study of sertraline in the prevention of depression in stroke patients. Psychosomatics 44:216–221.
Remick RA, Froese C, Keller FD (1989). Common side effects associated with monoamine oxidase inhibitors. Prog Neuropsychopharmacol Biol Psychiatry 13:497–504.
Richter K, Kellner S, Licht C (2023). rTMS in mental health disorders. Front Netw Physiol 3:943223.
Robinson RG, Jorge RE (2016). Post-stroke depression: a review. Am J Psychiatry 173:221–231.
Robinson RG, Starkstein SE (1990). Current research in affective disorders following stroke. J Neuropsychiatry Clin Neurosci 2:1–14.
Robinson RG, Starr LB, Kubos KL, Price TR (1983). A two-year longitudinal study of post-stroke mood disorders: findings during the initial evaluation. Stroke 14:736–741.
Robinson RG, Kubos KL, Starr LB, Rao K, Price TR (1984). Mood disorders in stroke patients Importance of location of lesion. Brain 107(Pt 1):81–93.
Robinson RG, Schultz SK, Castillo C, Kopel T, Kosier JT, Newman RM, et al. (2000). Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry 157:351–359.
Robinson RG, Jorge RE, Moser DJ, Acion L, Solodkin A, Small SL, et al. (2008). Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial. JAMA 299:2391–2400.
Rossi S, Antal A, Bestmann S, Bikson M, Brewer C, Brockmoller J, et al.; basis of this article began with a Consensus Statement from the IFCN Workshop on "Present, Future of TMS: Safety, Ethical Guidelines", Siena, October 17-20, 2018, updating through April 2020 (2021). Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: expert guidelines. Clin Neurophysiol 132:269–306.
Sekhon S, Gupta V (2020). Mood Disorder. StatPearls. Treasure Island (FL).
Sethi JK, Hotamisligil GS (2021). Metabolic Messengers: tumour necrosis factor. Nat Metab 3:1302–1312.
Shelton RC (2019). Serotonin and norepinephrine reuptake inhibitors. Handb Exp Pharmacol 250:145–180.
Shima S (1997). The efficacy of antidepressants in post-stroke depression. Keio J Med 46:25–26.
Sinyor D, Jacques P, Kaloupek DG, Becker R, Goldenberg M, Coopersmith H (1986). Poststroke depression and lesion location an attempted replication. Brain 109 (Pt 3):537–546.
Sohel AJ, Shutter MC, Molla M. (2023). Fluoxetine. StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Mollie Shutter declares no relevant financial relationships with ineligible companies. Disclosure: Mohammed Molla declares no relevant financial relationships with ineligible companies.
Song J, Kim E, Kim CH, Song HT, Lee JE (2015). The role of orexin in post-stroke inflammation, cognitive decline, and depression. Mol Brain 8:16.
Sparing R, Mottaghy FM (2008). Noninvasive brain stimulation with transcranial magnetic or direct current stimulation (TMS/tDCS)-From insights into human memory to therapy of its dysfunction. Methods 44:329–337.
Starkstein SE, Mizrahi R, Power BD (2008). Antidepressant therapy in post-stroke depression. Expert Opin Pharmacother 9:1291–1298.
Stroetmann KA, Stroetmann VN, Westerteicher C (2003). Implementation of TeleCare services: benefit assessment and organisational models. Stud Health Technol Inform 97:131–141.
Swartz RH, Bayley M, Lanctot KL, Murray BJ, Cayley ML, Lien K, et al. (2016). Post-stroke depression, obstructive sleep apnea, and cognitive impairment: rationale for, and barriers to, routine screening. Int J Stroke 11:509–518.
Szczepanska-Gieracha J, Cieslik B, Rutkowski S, Kiper P, Turolla A (2020). What can virtual reality offer to stroke patients? A narrative review of the literature. NeuroRehabilitation 47:109–120.
Tatsumi M, Groshan K, Blakely RD, Richelson E (1997). Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 340:249–258.
Tay J, Morris RG, Markus HS (2021). Apathy after stroke: diagnosis, mechanisms, consequences, and treatment. Int J Stroke 16:510–518.
Taylor WD, Aizenstein HJ, Alexopoulos GS (2013). The vascular depression hypothesis: mechanisms linking vascular disease with depression. Mol Psychiatry 18:963–974.
Thomas SA, Walker MF, Macniven JA, Haworth H, Lincoln NB (2013). Communication and Low Mood (CALM): a randomized controlled trial of behavioural therapy for stroke patients with aphasia. Clin Rehabil 27:398–408.
Thomas PD, Hill DP, Mi H, Osumi-Sutherland D, Van Auken K, Carbon S, et al. (2019). Gene Ontology Causal Activity Modeling (GO-CAM) moves beyond GO annotations to structured descriptions of biological functions and systems. Nat Genet 51:1429–1433.
Tiller JW (1992). Post-stroke depression. Psychopharmacology (Berl) 106(Suppl):S130–S133.
Torrisi M, Maresca G, De Cola MC, Cannavo A, Sciarrone F, Silvestri G, et al. (2019). Using telerehabilitation to improve cognitive function in post-stroke survivors: is this the time for the continuity of care? Int J Rehabil Res 42:344–351.
Towfighi A, Ovbiagele B, El Husseini N, Hackett ML, Jorge RE, Kissela BM, et al.; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research (2017). Poststroke Depression: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 48:e30–e43.
Tune LE (2001). Anticholinergic effects of medication in elderly patients. J Clin Psychiatry 62(Suppl 21):11–14.
Uzoni A, Ciobanu O, Sandu RE, Buga AM, Popa-Wagner A (2015). Life style, perfusion deficits and co-morbidities precipitate inflammation and cerebrovascular disorders in aged subjects. Discoveries (Craiova) 3:e39.
Villa RF, Ferrari F, Moretti A (2018). Post-stroke depression: mechanisms and pharmacological treatment. Pharmacol Ther 184:131–144.
Wade DT, Legh-Smith J, Hewer RA (1987). Depressed mood after stroke a community study of its frequency. Br J Psychiatry 151:200–205.
Wang Y, Shen J, Wang XM, Fu DL, Chen CY, Lu LY, et al. (2012). Scalp acupuncture for acute ischemic stroke: a meta-analysis of randomized controlled trials. Evid Based Complement Alternat Med 2012:480950.
Wang SB, Wang YY, Zhang QE, Wu SL, Ng CH, Ungvari GS, et al. (2018). Cognitive behavioral therapy for post-stroke depression: a meta-analysis. J Affect Disord 235:589–596.
Wang Y, Zhang X, Wang Y, Lu L, Wei R, Xu B, et al. (2023). Effects of combined live bifidobacterium, lactobacillus, enterococcus and bacillus cereus tablets on post-stroke depression and serum inflammatory factorse. Discov Med 35:312–320.
Weixlbaumer V, Draxler L, Zeitlinger M, Prantl B (2020). From St John’s wort to tomato and from Rhodiola to cranberry: a review of phytotherapy and some examples. Wien Klin Wochenschr 132:253–259.
Williams LS, Weinberger M, Harris LE, Clark DO, Biller J (1999). Development of a stroke-specific quality of life scale. Stroke 30:1362–1369.
Yao XW, Li YL, Yu ZJ, Mo CY, Pan HS, Li CY (2021). The efficacy and safety of agomelatine, sertraline, and escitalopram for senile post-stroke depression: a randomized double-blind placebo-controlled trial. Clin Neurol Neurosurg 205:106651.
Zhang SH, Wang YL, Zhang CX, Zhang CP, Xiao P, Li QF, et al. (2022). Effect of interactive dynamic scalp acupuncture on post-stroke cognitive function, depression, and anxiety: a multicenter, randomized, controlled trial. Chin J Integr Med 28:106–115.
Zhang J, Ming S, Chen X, Zhang T, Qian H, Peng S, et al. (2023). Herbal medicine as adjunctive therapy with antidepressants for post-stroke depression: a systematic review and network meta-analysis of randomized controlled trials. Front Pharmacol 14:1180071.
Zhao F, Yue Y, Jiang H, Yuan Y (2019). Shared genetic risk factors for depression and stroke. Prog Neuropsychopharmacol Biol Psychiatry 93:55–70.
Zhao T, Sun S, Gao Y, Rong Y, Wang H, Qi S, et al. (2023). Luteolin and triptolide: potential therapeutic compounds for post-stroke depression via protein STAT. Heliyon 9:e18622.
Zheng Z, Li C, Fu F, Xie H, Pan Y, Liao J, et al. (2023). Effectiveness of telehealth interventions on depression symptoms after stroke: a systematic review and meta-analysis. J Affect Disord 337:215–222.
Zhong D, Cheng H, Pan Z, Ou X, Liu P, Kong X, et al. (2023). Efficacy of scalp acupuncture combined with conventional therapy in the intervention of post-stroke depression: a systematic review and meta-analysis. Complement Ther Med 77:102975.
Zhou S, Liu S, Liu X, Zhuang W (2020). Selective serotonin reuptake inhibitors for functional independence and depression prevention in early stage of post-stroke: a meta-analysis. Medicine (Baltim) 99:e19062.
Zhuang Y, Xing JJ, Li J, Zeng BY, Liang FR (2013). History of acupuncture research. Int Rev Neurobiol 111:1–23.
Zigmond AS, Snaith RP (1983). The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361–370.
Zung WW (1965). A self-rating depression scale. Arch Gen Psychiatry 12:63–70.